BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Alkem Laboratories Launches Kojiglo Serum for Facial Hyperpigmentation

Synopsis:

Alkem Laboratories has launched Kojiglo serum in India for facial hyperpigmentation. The serum, featuring Duo-Lipo technology, enhances skin absorption and efficacy. It includes active ingredients such as liposomal azelaic acid and niacinamide. Alkem Laboratories Ltd. share price closed at ₹5,107.80, up by 1.27 percent.


Alkem Laboratories has launched Kojiglo serum in India, marking a significant expansion in its skincare portfolio. The serum features Duo-Lipo technology, a formulation designed to improve skin absorption and enhance efficacy. It includes active ingredients such as liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide. These components help in reducing facial hyperpigmentation while minimising skin irritation. The serum aims to provide a dermatologically advanced solution for individuals dealing with uneven skin tone and dark spots.

Also read: Godfrey Phillips Faces ₹166 Crore GST Demand, Plans to Appeal

ALKEM LABORATORIES LTD.

Trade

4847.51.00 (0.02 %)

Updated - 13 June 2025
4855.00day high
DAY HIGH
4743.50day low
DAY LOW
382701
VOLUME (BSE)

Key Takeaways

  • Alkem Laboratories has launched Kojiglo serum in India for facial hyperpigmentation.

  • It is the first liposomal serum with Duo-Lipo technology in India.

  • The formula contains azelaic acid, 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.

  • The serum enhances skin absorption and reduces sensitivity risks.

  • Alkem leads the demelanising category with its Kojiglo product line.

  • Kojiglo serum is available only on prescription.

  • Alkem Laboratories Ltd. share price closed at ₹5,107.80, rising by 1.27 percent.

Also read: RVNL Secures ₹404 Crore Project from East Coast Railway

Market Impact and Growth Strategy

Alkem Laboratories has a strong presence in the demelanising category with existing products like Kojiglo cream, Kojiglo face wash, and Kojiglo lotion. According to SMSRC data for October 2024, Kojiglo is the top-prescribed brand in this category by dermatologists. The introduction of Kojiglo serum aligns with the company’s strategy to expand its dermatology segment and strengthen its market share in skincare solutions.

Kojiglo Serum: Key Ingredients and Benefits

Ingredient

Benefit

Liposomal Azelaic Acid

Reduces hyperpigmentation and evens skin tone

Liposomal 4-Butyl Resorcinol

Inhibits melanin production for brighter skin

Tranexamic Acid

Reduces dark spots and prevents pigmentation

Alpha Arbutin

Lightens dark patches and promotes an even skin tone

Niacinamide

Enhances skin barrier and reduces redness

Market Performance and Alkem Laboratories Ltd. Share Price

The launch of Kojiglo serum has further solidified Alkem Laboratories’ position in the skincare industry. Investors responded positively, with Alkem Laboratories Ltd. share price rising by 1.27 percent, closing at ₹5,107.80 on the Bombay Stock Exchange. The company’s strategic focus on dermatology and innovative formulations has contributed to its market growth.

The launch of Kojiglo serum underscores Alkem Laboratories’ commitment to dermatological advancements. With its cutting-edge formulation and prescription-based availability, the product is set to make a mark in the hyperpigmentation treatment segment. Alkem Laboratories Ltd. share price gained traction, reflecting strong investor confidence in the company’s expanding skincare portfolio.

Also read: Lupin Gets Tentative USFDA Nod for HIV Drug, Shares Surge 3

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.4 App Rating

icon-with-text

4 Languages

icon-with-text

₹5100+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|